Gut bacteria joins fight against advanced kidney cancer
NCT ID NCT07128680
Summary
This early-stage study is testing whether adding a specific gut bacteria supplement, called EXL01, makes standard immunotherapy drugs (nivolumab and ipilimumab) safer and more effective for people with advanced kidney cancer that has spread. The goal is to see if changing the gut's bacteria can help the patient's own immune system better attack the cancer. The study will enroll about 33 adults who have not yet received treatment for their metastatic kidney cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope Medical Center
NOT_YET_RECRUITINGIrvine, California, 92618, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.